Status:
RECRUITING
Purinergic Signaling and the Postmenopausal Heart
Lead Sponsor:
Beth Israel Deaconess Medical Center
Conditions:
Diastolic Heart Failure
Heart Failure With Preserved Ejection Fraction
Eligibility:
All Genders
30-88 years
Brief Summary
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through puri...
Detailed Description
Cardiovascular disease (CVD) is the leading cause of death of women in the United States, accounting for around 1 of every 3 deaths. Estrogen deficiency, as seen in aging women or after oophorectomy, ...
Eligibility Criteria
Inclusion
- Patients undergoing cardiac surgery under cardiopulmonary bypass.
Exclusion
- Refusal to participate
- Emergency surgery
- Pre-existing heart block
- Preexisting atrial fibrillation
- Redo surgery
- Estrogen or hormone replacement therapy
- History of chronic heart failure
- History of major kidney disease
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06015776
Start Date
July 1 2019
End Date
June 1 2025
Last Update
October 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215